Morera Y, Bequet M, Ayala M, Gavilondo JV, Castro J, Puente P, Ancízar J, Suarez J, Sanchez J, Cosme K, Bacardí D, Acevedo BE

Language: English
References: 8
Page: 118-121
PDF size: 155.13 Kb.

ABSTRACT

ABSTRACT CIGB-247 is a novel cancer therapeutic vaccine that uses a mutated form of human vascular endothelial growth factor (VEGF) as antigen in combination with the oil-free adjuvant VSSP (very small sized proteoliposomes of Neisseria meningitidis outer membrane). The vaccine was designed to affect tumor neo-vascularization and tumor cell viability by eliciting antibodies that block the interaction of VEGF and its receptors in activated endothelial cells, as well as specific cytotoxic T cells that can directly destroy tumor and tumor stroma cells producing VEGF. Our previous experimental studies with CIGB-247 in mice, in which VEGF shares an 87% homology to the human molecule, have shown that the vaccine has anti-tumoral and anti-metastatic activity, and produces anti-VEGF antibodies and a specific T cell cytotoxic response against tumor cells. Herein we extend the immunogenicity and safety studies of CIGB-247 in mice, rats, rabbits and non-human primates. All the species develop antigen-specific IgG antibodies able to block the interaction of VEGF and VEGF receptor 2 in an ELISA assay. Purified IgG from CIGB-247 immunized monkey sera effectively impair human microvascular endothelial cells’ proliferation and capillary-like structures formation in MatrigelTM. In monkeys and mice, DTH and direct cell cytotoxicity experiments suggest that specific T cell responses are elicited after vaccination. Immunization with CIGB-247 does not affect animal behavior, hematology counts, blood biochemistry or histology of critical organs. Skin deep wound healing was not affected in vaccinated rats and monkeys. Altogether, these results support further clinical development of CIGB-247 therapeutic cancer vaccine, and shed light on the potential mechanisms underlying its effects.

REFERENCES

1. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009;335(1):261-9.

2. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6(8):465-77.

3. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS. 2005(94):209-31.

4. Morera Y, Bequet-Romero M, Ayala M, Lamdan H, Agger EM, Andersen P, et al. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis. 2008;11(4):381-93.

5. Bequet-Romero M, Morera Y, Ayala-Avila M, Ancizar J, Soria Y, Blanco A, et al. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors. Vaccine. 2012;30(10):1790-9.

6. Morera Y, Bequet-Romero M, Ayala M, Velazco JC, Perez PP, Alba JS, et al. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine. 2010;28(19):3453-61.

7. Morera Y, Bequet-Romero M, Ayala M, Perez PP, Castro J, Sanchez J, et al. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine. 2012;30(2):368-77.

8. Costa R, Carneiro A, Rocha A, Pirraco A, Falcao M, Vasques L, et al. Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study. J Cell Biochem. 2009;108(6):1410-7.